PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood-Brain Barrier Models
Kirchner, J.; Völker, E.; Shityakov, S.; Saji, S.; Förster, C.Y. Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood–Brain Barrier Models. International Journal of Molecular Sciences 2024, 25, 3379, doi:10.3390/ijms25063379.
Kirchner, J.; Völker, E.; Shityakov, S.; Saji, S.; Förster, C.Y. Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood–Brain Barrier Models. International Journal of Molecular Sciences 2024, 25, 3379, doi:10.3390/ijms25063379.
Kirchner, J.; Völker, E.; Shityakov, S.; Saji, S.; Förster, C.Y. Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood–Brain Barrier Models. International Journal of Molecular Sciences 2024, 25, 3379, doi:10.3390/ijms25063379.
Kirchner, J.; Völker, E.; Shityakov, S.; Saji, S.; Förster, C.Y. Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor β Agonists and In Vitro Blood–Brain Barrier Models. International Journal of Molecular Sciences 2024, 25, 3379, doi:10.3390/ijms25063379.
Abstract
Breast cancer brain metastasis (BCBM) is a challenging condition with limited treatment options and poor prognosis. Understanding the interactions between tumor cells and the blood-brain barrier (BBB) is critical for developing novel therapeutic strategies. One promising target is estrogen receptor β (ERβ), which promotes the expression of key tight junction proteins, sealing the BBB and reducing its permeability. In this study, we investigated the effects of 17β-estradiol (E2) and the selective ERβ agonist diarylpropionitrile (DPN) on endothelial and cancer cells. Western blot analysis revealed the expression patterns of ERs in these cell lines, and estrogen treatment upregulated claudin-5 expression in brain endothelial cells. Using in vitro models of the BBB, we found that DPN treatment significantly increased BBB tightness about suppressed BBB transmigration activity of representative HER2-positive (BT-474) and triple-negative (MDA-MB-231) breast cancer cell lines. However, the efficacy of DPN treatment decreased when cancer cells were pre-differentiated in the presence of E2. Our results support ERβ as a potential target for the prevention and treatment of BCBM and suggest that targeted vector-based approaches may be effective for future preventive and therapeutic implications.
Keywords
breast cancer brain metastasis; targeted therapy;
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
